Singapore, November 14, 2018 – The Russian Direct Investment Fund (“RDIF”), Russia’s sovereign wealth fund, Singapore’s Asian American Medical Group (“AAMG”), and JSC Rusatom Healthcare, a subsidiary of Russia’s State Atomic Energy Corporation Rosatom (“Rosatom”), have agreed to jointly develop a nuclear medicine center in Iskandar Puteri, Malaysia.
The proposed project involves the creation of a modern medical institution specializing in the diagnosis and treatment of cancer. The center, neighboring Singapore, will include departments specializing in radionuclide diagnostics, radionuclide therapy, radiation therapy and a cyclotron based radiochemistry facility among others.
The project will combine the financial resources of RDIF and Rosatom and technical expertise of Rosatom – which specializes in domestic and international promotion of Russian nuclear technology for medicine – with AAMG, a healthcare specialist based in Singapore which is listed on the Australian Securities Exchange.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF), said:
“Nuclear medicine is a promising high-tech specialty for the diagnosis and treatment of cancer. In Russia, this area is rapidly developing, and the expanded use of Russian technologies abroad supports this development. We are pleased to be able to support this process by implementing a project to build a nuclear medicine center in Malaysia. This will ensure the export of Russian technologies and support Rosatom’s entry to the international market.”
Denis Cherednichenko, CEO of JSC Rusatom Healthcare, said:
“The agreement signed shows high demand for Russian medical technologies on the rapidly developing markets of the Asia-Pacific region that we consider today as core markets for us. The implementation of this project will create additional competitive advantages and open new opportunities in foreign markets.”
Dato’ Dr Tan Kai Chah, Executive Chairman of AAMG, said:
“We are highly encouraged by the commitment of RDIF to participate with JSC Rusatom Healthcare and AAMG to bring medical excellence in Southeast Asia to a whole new level. Through nuclear medicine the diagnosis and treatment of cancer victims can improve significantly. There is already increasing understanding, effectiveness and safety aspects of nuclear medicine. I sincerely believe this proposed nuclear medicine centre will be a leader in providing the best oncological care in Southeast Asia.”
Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Further information can be found at www.rdif.ru
Asian American Medical Group (AAMG) is a health care group founded in 1994 and headquartered in Singapore. AAMG has been listed on the Australian Securities Exchange since September 2009 and is focused on providing treatment of liver diseases, radiation and oncology treatment, health care management and consultancy and also health care real estate development. Further information can be found at www.aamg.co
JSC Rusatom Healthcare was established by JSC Atomenergoprom as part of Rosatom State Corporation to develop the production of equipment and radionuclide products for nuclear medicine and medical radiology, as well as industrial equipment based on radiation technologies. The strategic goal of JSC Rusatom Healthcare is the organization and integration of production facilities to create a full-fledged domestic market of modern high-tech equipment and innovative radionuclide products and radiopharmaceuticals for nuclear medicine and medical radiology, as well as modern industrial equipment based on radiation technologies with the subsequent promotion of competitive products abroad.